|
See related Puregon inj information |
|
|
|
Manufacturer |
MSD |
|
Distributor |
Hong Kong: DKSH |
|
Contents |
Follitropin β |
|
Indications |
Female Anovulation including polycystic ovarian disease (PCOD) in women unresponsive to clomiphene citrate. Controlled ovarian hyperstimulation (COH) in medically-assisted reproduction programmes eg IVF/ET, GIFT & ICSI. Male Deficient spermatogenesis due to hypogonadotrophic hypogonadism. |
|
Dosage |
Slow IM/SC. Female Anovulation 50 IU/day for 7-14 days. COH 100-225 IU for at least the 1st 4 days. Maintenance: 73-375 IU for 6-12 days or longer. Male 450 IU/wk in 3 divided dosage of 150 iu concomitantly w/ HCG for at least 3-4 mth. |
|
Contraindications |
Tumours of the ovary, breast, uterus, testis, pituitary or hypothalamus; primary gonadal failure. Female: Pregnancy; undiagnosed vag bleeding; ovarian cysts or enlarged ovaries not related to PCOD; malformations of the reproductive organs incompatible w/ pregnancy; fibroid tumours of the uterus incompatible w/ pregnancy. |
|
Special Precautions |
Presence of uncontrolled non-gonadal endocrinopathies should be excluded. Hypersensitivity to streptomycin &/or neomycin. Female Unwanted ovarian hyperstimulation; risk for thrombosis; severe obesity or thrombophilia, increased risk of venous or arterial thrombo-embolic events; increased risk of multiple gestation & ectopic pregnancy. Early ultrasound is important. Male Elevated FSH levels is unresponsive to Puregon/hCG therapy. |
|
Adverse Drug Reactions |
Headache. Female Abdominal distension & pain; OHSS; pelvic pain; inj site reaction. Male Acne, rash, epididymal cyst; gynaecomastia; inj site induration.
View ADR Monitoring Form |
|
Drug Interactions |
Concomitant use w/ clomiphene citrate may enhance follicular response. A higher dose may be needed after pituitary desensitisation induced by a GnRH agonist.
View more drug interactions with Puregon |
|
Pregnancy Category (US FDA) |
Category X: Studies in animals or human beings have demonstrated foetal abnormalities or there is evidence of foetal risk based on human experience or both, and the risk of the use of the drug in pregnant women clearly outweighs any possible benefit. The drug is contraindicated in women who are or may become pregnant. |
|
ATC Classification |
G03GA06 - follitropin beta ; Belongs to the class of gonadotropins. Used as ovulation stimulants. |
|
Presentation/Packing |
|
Form |
Packing |
Photo |
|
Puregon injection |
|
Puregon (Vial) 50 IU x 1's |
|
Puregon (Vial) 100 IU x 1's |
|
Puregon (Cartridge) 300 IU x 1's |
|
Puregon (Cartridge) 600 IU x 1's |
|
|
|
Manufacturer: |
MSD |
|
Distributor: |
Hong Kong: DKSH
|
|
|
|
